Drug Trial Radar · NCT00394277
A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C
Last checked: Nov 20, 2026Latest source record: Aug 3, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,175
Actual
Start
Feb 2007
Primary completion
Apr 2009
Study completion Apr 2009
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 31, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 4-arm study will compare the efficacy and safety of PEGASYS induction and maintenance dosing, versus standard fixed dosing in combination with Copegus, and the efficacy and safety of higher dose versus standard dose Copegus in combination with PEGASYS. Patients with chronic hepatitis C (CHC) genotype 1 infection of high viral titer, and baseline body weight ≥85 kg, will be randomized to one of 4 groups, to receive one of the following: a) PEGASYS 180 µg subcutaneously (sc) weekly plus Copegus 1200 mg orally (po) daily; b) PEGASYS 180 µg sc weekly plus Copegus 1400-1600 mg po daily; c)PEGASYS 360 µg sc weekly (induction) followed by 180 µg sc weekly (maintenance) plus Copegus 1200 mg po daily; or d) PEGASYS 360 µg sc weekly (induction) followed by 180 µg sc weekly (maintenance) plus Copegus 1400-1600 mg po daily. Following 48 weeks treatment, there will be a 24-week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.
Conditions
- Hepatitis C, Chronic
Interventions
peginterferon alfa-2aDrug
180 µg sc weekly for 48 weeks
RibavirinDrug
1200 mg po daily for 48 weeks
peginterferon alfa-2aDrug
360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks
RibavirinDrug
1400-1600 mg po daily for 48 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained Virological Response (SVR)-24 (Scheduled Treatment Period)Time frame: Week 72
Locations
184 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Huntsville, Alabama
Site not named
Anchorage, Alaska
Site not named
Phoenix, Arizona
Site not named
Fresno, California
Site not named
La Jolla, California
Site not named
Lancaster, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
San Luis Obispo, California
Site not named
San Marcos, California
Site not named
Ventura, California
Site not named
Aurora, Colorado
Site not named
Englewood, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Washington D.C., District of Columbia
Site not named
Jacksonville, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
North Miami Beach, Florida
Site not named
Sarasota, Florida
Site not named
Atlanta, Georgia
Site not named
Austell, Georgia
Site not named
Marietta, Georgia
Site not named
Honolulu, Hawaii
Site not named
Chicago, Illinois
Site not named
Chicago, Illinois
Site not named
Winfield, Illinois
Site not named
Indianapolis, Indiana
Site not named
Des Moines, Iowa
Site not named
Iowa City, Iowa
Site not named
Iowa City, Iowa
Site not named
Louisville, Kentucky
Site not named
Baton Rouge, Louisiana
Site not named
New Orleans, Louisiana
Showing 40 of 184 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.